Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A HorwichS P Stenning

Abstract

This prospective randomized multicenter trial was designed to evaluate the efficacy of carboplatin plus etoposide and bleomycin (CEB) versus cisplatin plus etoposide and bleomycin (BEP) in first-line chemotherapy of patients with good-risk nonseminomatous germ cell tumors. Between September 1989 and May 1993, a total of 598 patients with good-risk nonseminomatous germ cell tumors were randomized to receive four cycles of either BEP or CEB. In each cycle, the etoposide dose was 120 mg/m2 on days 1, 2, and 3, and the bleomycin dose was 30 U on day 2. BEP patients received cisplatin at 20 mg/m2/d on days 1 to 5 or 50 mg/m2 on days 1 and 2. For CEB patients, the carboplatin dose was calculated from the glomerular filtration rate to achieve a serum concentration x time of 5 mg/mL x minutes. Chemotherapy was recycled at 21-day intervals to a total of four cycles. Of patients assessable for response, 253 of 268 (94.4%) of those allocated to receive BEP achieved a complete response, compared with 227 of 260 (87.3%) allocated to receive CEB (P = .009). There were 30 treatment failures in the 300 patients allocated to BEP and 79 in the 298 allocated to CEB (log-rank chi 2 = 26.9; P < .001), which led to failure-free rates at 1 year of 91...Continue Reading

Citations

Dec 10, 1999·Seminars in Surgical Oncology·G J Bosl
Apr 11, 2000·Cancer Control : Journal of the Moffitt Cancer Center·P Benedetto
Sep 21, 2001·Journal of Pediatric Hematology/oncology·M A Smith, B Anderson
Jan 22, 2002·American Journal of Clinical Oncology·E W WinquistJ Balogh
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan OldenburgSophie D Fossa
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald de Wit, Karim Fizazi
Aug 3, 2007·Journal of Drug Targeting·Yasuhiro Matsumura
Oct 9, 2007·Nature Clinical Practice. Urology·Tim Oliver
Apr 10, 2008·Nature Clinical Practice. Urology·Aude FléchonJean-Pierre Droz
Oct 1, 2008·British Journal of Cancer·R A Huddart
Nov 11, 2008·Journal of Hematology & Oncology·Darren R Feldman, George J Bosl
Feb 6, 2009·Expert Review of Anticancer Therapy·Duncan C GilbertRobert A Huddart
Mar 3, 2009·Der Urologe. Ausg. A·A HeidenreichR Souchon
May 23, 2009·Cancer Science·Yasuhiro Matsumura, Kazunori Kataoka
Jun 11, 2009·World Journal of Urology·Darren R Feldman, Robert J Motzer
Oct 21, 2009·BJU International·Monique M TroostRonald de Wit
Jul 16, 2010·Journal of the National Cancer Institute·Craig Nichols, Christian Kollmannsberger
Oct 20, 2010·BJU International·Frank MayerFriedemann Honecker
Jul 16, 2010·Journal of the National Cancer Institute·Peter S GrimisonGuy C Toner
Jul 14, 2010·Southern Medical Journal·Tamim HamdiAshok Patel
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mette SprautenLois B Travis
Nov 22, 2011·Expert Opinion on Drug Metabolism & Toxicology·Gury DoshiCora N Sternberg
Feb 28, 2013·Japanese Journal of Clinical Oncology·Seiji NihoYuichiro Ohe
Jan 1, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Alpaslan OzgunOguz Bilgi
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Tarkan YetisyigitNecati Alkis
May 27, 2014·American Society of Clinical Oncology Educational Book·Hege Sagstuen HaugnesDarren Richard Feldman
Jan 28, 2017·Indian Journal of Surgical Oncology·Puneet Ahluwalia, Gagan Gautam
May 9, 2019·Pediatric Blood & Cancer·Sara StonehamLindsay Frazier
Aug 12, 1999·BJU International·G M Mead
Jun 1, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Culine, J P Droz
Aug 7, 2003·Journal of the National Cancer Institute·Janessa LaskinDavid H Johnson
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H MeyerB D Fletcher
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G Varuni Kondagunta, Robert J Motzer
Mar 11, 2005·Expert Review of Anticancer Therapy·Robert A Huddart, Alison J Birtle
Jul 5, 2005·Expert Opinion on Investigational Drugs·J P Droz, S Culine
Jul 25, 2007·Oncology·Dimitrios PectasidesMelina Pectasides
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neyssa MarinaThomas Olson
Jan 31, 2013·Korean journal of urology·Yu Seob Shin, Hyung Jin Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D F BajorinP Sogani
Journal of Pediatric Hematology/oncology
G KapoorP B Desai
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P S GrimisonAustralian and New Zealand Urogenital and Prostate Cancer Trials Group
© 2021 Meta ULC. All rights reserved